T-DM1

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

T-DM1
Sep 7, 2024, 19:36 | Insight
A year of treatment with an ADC has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared the following on LinkedIn: “A year of treatment with a medicine…
Jul 2, 2024, 10:32 | Insight
Trastuzumab emtansine (T-DM1) is highly effective in preventing stage 1 HER2-positive breast cancer from recurring - MedEdge MEA
MedEdge MEA shared a post on LinkedIn:  . "A year of treatment with a medicine…
Jul 1, 2024, 18:24 | Insight
Paolo Tarantino: How long should adjuvant T-DM1 be given for stage I HER2+ eBC?
Paolo Tarantino shared on X: "For how long should adjuvant T-DM1 be given for stage…
Jun 17, 2024, 20:15 | Insight
Elisa Agostinetto: Commentary on the updated results of DestinyBreast03
Elisa Agostinetto shared on X/Twitter: "Out commentary on the updated results of DestinyBreast03 is out…
May 2, 2024, 15:20 | Blog
Paolo Tarantino: Impressive to think at the journey of ADCs over the last five years
Paolo Tarantino shared on LinkedIn: "Impressive to think at the journey of ADCs over the last…
Apr 27, 2024, 15:34 | Insight
Erika Hamilton: Happy to share our publication re: T-DXd vs. T-DM1 among patients with brain metastasis in DB-03
Erika Hamilton shared on LinkedIn: "Happy to share our publication re: T-DXd vs. T-DM1 among…
Dec 30, 2023, 17:51 | Opinion
Paolo Tarantino: Happy to have worked with Sarah Sammons and Nancy Lin at the ph2 DATO-Base trial
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared a post…
All: 7 Posts: 1 - 100
Special Coverage